memantine has been researched along with Brain Ischemia in 32 studies
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to investigate the effects of memantine on brain ischemia." | 7.88 | Effects of Memantine on Nitric Oxide Production and Hydroxyl Radical Metabolism during Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2018) |
| "Memantine prevented cerebral ischemia-induced brain infarct and neuronal injury, and reduced oxygen-glucose deprivation-induced cortical neuronal apoptosis." | 7.83 | Memantine mediates neuroprotection via regulating neurovascular unit in a mouse model of focal cerebral ischemia. ( Chen, ZZ; Ji, J; Sun, XL; Yan, H; Yang, DD; Zhao, Z, 2016) |
| "Combinations of memantine with clenbuterol extend the respective therapeutic window and provide synergistic cerebroprotective effects after stroke." | 7.72 | Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. ( Culmsee, C; Junker, V; Kremers, W; Krieglstein, J; Plesnila, N; Thal, S, 2004) |
| "Memantine is a US Food and Drug Administration approved drug for the treatment of Alzheimer's disease." | 6.61 | Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies. ( F Kallmes, D; Seyedsaadat, SM, 2019) |
| "An aim of the study was to investigate the efficacy and safety of noojerone (memantine) in patients with cognitive impairment comorbid to brain ischemia, stages II-III." | 5.17 | [Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment]. ( Litvinenko, IV; Lobzin, VY; Lupanov, IA; Vorob'ev, SV, 2013) |
| "The purpose of this study was to investigate the effects of memantine on brain ischemia." | 3.88 | Effects of Memantine on Nitric Oxide Production and Hydroxyl Radical Metabolism during Cerebral Ischemia and Reperfusion in Mice. ( Araki, N; Hirayama, M; Ishizawa, K; Ito, Y; Kawasaki, H; Kitabayashi, C; Nagai, T; Nishioka, R; Takahashi, K; Tanaka, A; Yamamoto, T; Yamazato, M, 2018) |
| "Memantine prevented cerebral ischemia-induced brain infarct and neuronal injury, and reduced oxygen-glucose deprivation-induced cortical neuronal apoptosis." | 3.83 | Memantine mediates neuroprotection via regulating neurovascular unit in a mouse model of focal cerebral ischemia. ( Chen, ZZ; Ji, J; Sun, XL; Yan, H; Yang, DD; Zhao, Z, 2016) |
| "Combinations of memantine with clenbuterol extend the respective therapeutic window and provide synergistic cerebroprotective effects after stroke." | 3.72 | Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. ( Culmsee, C; Junker, V; Kremers, W; Krieglstein, J; Plesnila, N; Thal, S, 2004) |
| "In this study the effect of memantine, an antagonist at the N-methyl-D-aspartate receptor, on spatial learning deficit and on neuronal damage following transient cerebral ischemia was evaluated." | 3.69 | Memantine reduces functional and morphological consequences induced by global ischemia in rats. ( Block, F; Schwarz, M, 1996) |
| "Multiple events occur in the postcardiac arrest period, including excitotoxicity, mitochondrial dysfunction, and oxidative stress and inflammation, all of which contribute to ongoing brain injury and cellular death." | 2.82 | Pharmacologic neuroprotection in ischemic brain injury after cardiac arrest. ( Brosnahan, SB; Katz, A; Lam, JQ; Papadopoulos, J; Parnia, S, 2022) |
| "Memantine is a US Food and Drug Administration approved drug for the treatment of Alzheimer's disease." | 2.61 | Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies. ( F Kallmes, D; Seyedsaadat, SM, 2019) |
| "Memantine is a non-competitive NMDA-receptor antagonist." | 2.49 | [Neuroprotective potential of akatinol-memantine in ischemic stroke]. ( Levin, OS; Makotrova, TA; Shrader, NI; Trusova, NA, 2013) |
| "Memantine was used as a positive control." | 1.43 | Low dose of L-glutamic acid attenuated the neurological dysfunctions and excitotoxicity in bilateral common carotid artery occluded mice. ( Abdul, KK; Justin, A; Ramanathan, M, 2016) |
| "S-memantine was synthesized by chemically combining a slow releasing H(2)S donor 4-(3-thioxo-3H-1,2-dithiol-4-yl)-benzoic acid (ACS48) with a NMDAR antagonist memantine." | 1.38 | A novel hydrogen sulfide-releasing N-methyl-D-aspartate receptor antagonist prevents ischemic neuronal death. ( Arai, K; Atochin, DN; Ichinose, F; Khatri, A; Kida, K; Kosugi, S; Marutani, E; Nguyen, R; Tokuda, K; Van Leyen, K, 2012) |
| "Treatment of cerebral edema could not be investigated because formation of cerebral edema could not be proven statistically." | 1.35 | Effects of memantine and MK-801 on ischemia in an experimental model of acute subdural hematoma. ( Aktan, D; Arica, O; Görgülü, A; Kirin, T; Sencer, A, 2008) |
| "Memantine is a noncompetitive NMDA receptor antagonist and it has been used for the treatment of various cerebral disorders with relatively few side effects." | 1.31 | Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. ( Cobanoglu, S; Görgülü, A; Izgi, NI; Kinş, T; Küçük, M; Unal, F; Yanik, B, 2000) |
| "Memantine has been used clinically in the treatment of Parkinson's disease and spasticity for a number of years." | 1.30 | Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. ( Le, DA; Lipton, SA; Sathi, S; Stieg, PE; Warach, S, 1999) |
| "To this end, we used a model of focal cerebral ischemia in mice and rats." | 1.28 | Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. ( Backhauss, C; Krieglstein, J, 1992) |
| " Dizocilpine was active in this model at a dosage of 1 mg/kg." | 1.28 | Neuroprotective effect of memantine demonstrated in vivo and in vitro. ( Krieglstein, J; Mennel, HD; Peruche, B; Rossberg, C; Seif el Nasr, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (18.75) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Katz, A | 1 |
| Brosnahan, SB | 1 |
| Papadopoulos, J | 1 |
| Parnia, S | 1 |
| Lam, JQ | 1 |
| Tanaka, A | 1 |
| Ito, Y | 1 |
| Kawasaki, H | 1 |
| Kitabayashi, C | 1 |
| Nishioka, R | 1 |
| Yamazato, M | 1 |
| Ishizawa, K | 1 |
| Nagai, T | 1 |
| Hirayama, M | 1 |
| Takahashi, K | 1 |
| Yamamoto, T | 1 |
| Araki, N | 1 |
| Seyedsaadat, SM | 1 |
| F Kallmes, D | 1 |
| Makotrova, TA | 1 |
| Trusova, NA | 1 |
| Shrader, NI | 1 |
| Levin, OS | 1 |
| Litvinenko, IV | 1 |
| Vorob'ev, SV | 1 |
| Lobzin, VY | 1 |
| Lupanov, IA | 1 |
| Makarewicz, D | 1 |
| Sulejczak, D | 1 |
| Duszczyk, M | 2 |
| Małek, M | 1 |
| Słomka, M | 1 |
| Lazarewicz, JW | 2 |
| Trotman, M | 1 |
| Vermehren, P | 1 |
| Gibson, CL | 1 |
| Fern, R | 1 |
| Li, WJ | 2 |
| Mao, FX | 2 |
| Chen, HJ | 2 |
| Qian, LH | 2 |
| Buzby, JS | 1 |
| Takahashi, H | 1 |
| Xia, P | 1 |
| Cui, J | 1 |
| Talantova, M | 1 |
| Bodhinathan, K | 1 |
| Li, W | 2 |
| Saleem, S | 1 |
| Holland, EA | 1 |
| Tong, G | 1 |
| Piña-Crespo, J | 1 |
| Zhang, D | 1 |
| Nakanishi, N | 1 |
| Larrick, JW | 1 |
| McKercher, SR | 1 |
| Nakamura, T | 1 |
| Wang, Y | 2 |
| Lipton, SA | 3 |
| Chen, ZZ | 1 |
| Yang, DD | 1 |
| Zhao, Z | 1 |
| Yan, H | 1 |
| Ji, J | 1 |
| Sun, XL | 1 |
| Wang, YC | 1 |
| Sanchez-Mendoza, EH | 1 |
| Doeppner, TR | 1 |
| Hermann, DM | 1 |
| Ramanathan, M | 1 |
| Abdul, KK | 1 |
| Justin, A | 1 |
| Chen, B | 1 |
| Wang, G | 1 |
| Liu, W | 1 |
| Lin, R | 1 |
| Tao, J | 1 |
| Jiang, M | 1 |
| Chen, L | 1 |
| Jung, KH | 1 |
| Chu, K | 1 |
| Lee, ST | 1 |
| Park, HK | 1 |
| Kim, JH | 1 |
| Kang, KM | 1 |
| Kim, M | 1 |
| Lee, SK | 1 |
| Roh, JK | 1 |
| Lorrio, S | 1 |
| Negredo, P | 1 |
| Roda, JM | 1 |
| García, AG | 1 |
| López, MG | 1 |
| Masuko, T | 1 |
| Suzuki, T | 1 |
| Miyake, M | 1 |
| Kusama-Eguchi, K | 1 |
| Kizawa, Y | 1 |
| Tomono, K | 1 |
| Kashiwagi, K | 1 |
| Igarashi, K | 1 |
| Kusama, T | 1 |
| Marutani, E | 1 |
| Kosugi, S | 1 |
| Tokuda, K | 1 |
| Khatri, A | 1 |
| Nguyen, R | 1 |
| Atochin, DN | 1 |
| Kida, K | 1 |
| Van Leyen, K | 1 |
| Arai, K | 1 |
| Ichinose, F | 1 |
| Winblad, B | 1 |
| Kivipelto, M | 1 |
| Culmsee, C | 1 |
| Junker, V | 1 |
| Kremers, W | 1 |
| Thal, S | 1 |
| Plesnila, N | 1 |
| Krieglstein, J | 4 |
| Frankiewicz, T | 1 |
| Parsons, CG | 1 |
| Kato, T | 1 |
| Gadamski, R | 1 |
| Ziembowicz, A | 1 |
| Danysz, W | 1 |
| Bakiri, Y | 1 |
| Hamilton, NB | 1 |
| Káradóttir, R | 1 |
| Attwell, D | 1 |
| Sencer, A | 1 |
| Arica, O | 1 |
| Kirin, T | 1 |
| Görgülü, A | 2 |
| Aktan, D | 1 |
| Block, F | 1 |
| Schwarz, M | 1 |
| Chen, HS | 1 |
| Wang, YF | 1 |
| Rayudu, PV | 1 |
| Edgecomb, P | 1 |
| Neill, JC | 1 |
| Segal, MM | 1 |
| Jensen, FE | 1 |
| Stieg, PE | 1 |
| Sathi, S | 1 |
| Warach, S | 1 |
| Le, DA | 1 |
| Kinş, T | 1 |
| Cobanoglu, S | 1 |
| Unal, F | 1 |
| Izgi, NI | 1 |
| Yanik, B | 1 |
| Küçük, M | 1 |
| Backhauss, C | 1 |
| Seif el Nasr, M | 1 |
| Peruche, B | 1 |
| Rossberg, C | 1 |
| Mennel, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for memantine and Brain Ischemia
| Article | Year |
|---|---|
Pharmacologic neuroprotection in ischemic brain injury after cardiac arrest.
Topics: Animals; Antioxidants; Brain Injuries; Brain Ischemia; Heart Arrest; Humans; Memantine; Neuroprotect | 2022 |
Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Humans; Memantine; Stroke; Tissue Plasminogen Activator; | 2019 |
[Neuroprotective potential of akatinol-memantine in ischemic stroke].
Topics: Animals; Apoptosis; Brain Ischemia; Excitatory Amino Acid Antagonists; Humans; Memantine; Neurons; T | 2013 |
Memantine offers new possibilities for the treatment of VaD.
Topics: Animals; Brain Ischemia; Clinical Trials as Topic; Cognition; Dementia, Vascular; Excitatory Amino A | 2002 |
[Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
Topics: Alzheimer Disease; Binding Sites; Brain Ischemia; Dizocilpine Maleate; Humans; Magnesium; Memantine; | 2004 |
Mechanisms of neuroprotective drug actions.
Topics: Animals; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Memantine; Neuroprotective Agents; | 1997 |
1 trial available for memantine and Brain Ischemia
| Article | Year |
|---|---|
[Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment].
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cognition Disorders; Excitatory Amino Acid Antagonists; Fem | 2013 |
25 other studies available for memantine and Brain Ischemia
| Article | Year |
|---|---|
Effects of Memantine on Nitric Oxide Production and Hydroxyl Radical Metabolism during Cerebral Ischemia and Reperfusion in Mice.
Topics: Animals; Antioxidants; Biomarkers; Blood Flow Velocity; Brain Ischemia; CA1 Region, Hippocampal; Cer | 2018 |
Delayed preconditioning with NMDA receptor antagonists in a rat model of perinatal asphyxia.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Brain; Brain Ischemia; Disease Models, Animal; Dizoc | 2014 |
The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Ischemia; Calcium Signaling; Cell Death; Cell | 2015 |
Treatment with UDP-glucose, GDNF, and memantine promotes SVZ and white matter self-repair by endogenous glial progenitor cells in neonatal rats with ischemic PVL.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cell Hypoxia; Cell Proliferation; Cell Survival; C | 2015 |
Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease.
Topics: Animals; Anura; Apoptosis; Brain Ischemia; Cerebrovascular Disorders; Long-Term Potentiation; Maze L | 2015 |
Memantine mediates neuroprotection via regulating neurovascular unit in a mouse model of focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Cerebral Veins; Collagen Type IV; Disks Large Homolog 4 Protein; Glucose; G | 2016 |
Post-acute delivery of memantine promotes post-ischemic neurological recovery, peri-infarct tissue remodeling, and contralesional brain plasticity.
Topics: Animals; Brain Infarction; Brain Ischemia; Infarction, Middle Cerebral Artery; Memantine; Mice; Mice | 2017 |
Low dose of L-glutamic acid attenuated the neurological dysfunctions and excitotoxicity in bilateral common carotid artery occluded mice.
Topics: Animals; Brain; Brain Ischemia; Carotid Artery, Common; Disease Models, Animal; Dose-Response Relati | 2016 |
Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Brain Ischemia; Calpain; Caspase 3; Cerebral Arteries; C | 2017 |
Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; Excitatory Amino Acid An | 2009 |
Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils.
Topics: Animals; Brain Ischemia; Caspase 3; Cell Survival; Cholinesterase Inhibitors; Galantamine; Gerbillin | 2009 |
Antagonism of NMDA receptors by butanesulfonyl-homospermine guanidine and neuroprotective effects in in vitro and in vivo.
Topics: Animals; Brain Ischemia; Cell Line, Tumor; Cell Survival; Excitatory Amino Acid Antagonists; Female; | 2012 |
A novel hydrogen sulfide-releasing N-methyl-D-aspartate receptor antagonist prevents ischemic neuronal death.
Topics: Animals; Brain Injuries; Brain Ischemia; Cell Death; Cell Line, Tumor; Cells, Cultured; Drug Design; | 2012 |
[Effect of single or combined application of UDP-glucose, GDNF and memantine on improvement of white matter injury in neonatal rats assessed with light and electron microscopy pathologically].
Topics: Animals; Brain Ischemia; Cerebral Ventricles; Female; Glial Cell Line-Derived Neurotrophic Factor; H | 2012 |
Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol.
Topics: Adrenergic beta-Agonists; Animals; Brain Ischemia; Cells, Cultured; Clenbuterol; Disease Models, Ani | 2004 |
Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices ex vivo.
Topics: Animals; Brain Ischemia; Cell Hypoxia; Drug Administration Schedule; Hippocampus; In Vitro Technique | 2004 |
NMDA receptor antagonism does not inhibit induction of ischemic tolerance in gerbil brain in vivo.
Topics: Animals; Body Temperature; Brain; Brain Ischemia; Carotid Arteries; Dizocilpine Maleate; Excitatory | 2005 |
Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter.
Topics: Action Potentials; Animals; Animals, Newborn; Brain Ischemia; Central Nervous System; Dizocilpine Ma | 2008 |
Effects of memantine and MK-801 on ischemia in an experimental model of acute subdural hematoma.
Topics: Animals; Brain Edema; Brain Ischemia; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino | 2008 |
Memantine reduces functional and morphological consequences induced by global ischemia in rats.
Topics: Animals; Brain Ischemia; Dopamine Agents; Hippocampus; Male; Maze Learning; Memantine; Neostriatum; | 1996 |
Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.
Topics: Animals; Body Temperature; Brain Ischemia; Cytoplasm; Excitatory Amino Acid Antagonists; Excitatory | 1998 |
Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat.
Topics: Animals; Animals, Newborn; Brain; Brain Ischemia; Cerebrovascular Disorders; Disease Models, Animal; | 1999 |
Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat.
Topics: Animals; Brain Edema; Brain Ischemia; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationsh | 2000 |
Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents.
Topics: Animals; Brain Ischemia; Cerebral Arteries; Cerebral Infarction; Kava; Male; Memantine; Mice; Plant | 1992 |
Neuroprotective effect of memantine demonstrated in vivo and in vitro.
Topics: Adenosine Triphosphate; Animals; Brain Ischemia; Cell Hypoxia; Cells, Cultured; Chick Embryo; Dizoci | 1990 |